#Hong Kong #Akeso #Ivonescimab #HER3 ADC

Akeso's Innovative HER3 ADC Technology Advances in Lung Cancer Trials

Akeso, Inc. has recently taken a groundbreaking step in the battle against lung cancer, announcing the initial dosing of its first patient in a Phase Ib/II clinical trial. This study focuses on the evaluation of Akeso's novel HER3 antibody-drug conjugate (ADC), known as AK138D1, both as a standalone treatment and in combination with ivonescimab, a PD-1/VEGF bispecific antibody.

Progress in Lung Cancer Research

The clinical trial aims to assess the efficacy of Akeso's latest IO2.0 + ADC2.0 therapeutic strategy across multiple treatment scenarios in advanced non-small cell lung cancer (NSCLC). This includes utilizing the drug as a first-line treatment, following patient resistance to EGFR-TKI therapies, and after immuno-chemotherapy has proven ineffective. Notably, HER3 expression has been associated with cancer progression and treatment resistance, making it a critical target in NSCLC.

Traditional HER3 ADCs encountered challenges due to toxicity, and none have yet gained approval for clinical use. Akeso's innovative strategy with AK138D1 aims to mitigate these concerns by improving the drug’s selectivity for cancer cells while minimizing off-target effects. The design of this next-generation ADC allows it to penetrate tumors more effectively, circumventing the binding site barriers and enhancing therapeutic outcomes.

Promising Early Results

Initial trials conducted in both China and Australia illustrate that AK138D1 has demonstrated strong anti-tumor activity. Significantly, patients reported a favorable safety profile with minimal hematologic toxicity, and no cases of interstitial lung disease were recorded, a common concern with lung cancer treatments.

The innovative ivonescimab antibody has also performed impressively in clinical scenarios, showing superior results compared to conventional PD-1 inhibitor therapies across various Phase III studies. The synergy between AK138D1 and ivonescimab could potentially enhance the immune system's capacity to fight tumors, providing a more robust treatment option for different subtypes of NSCLC without compromising safety.

Building a Comprehensive Treatment Matrix

Akeso is keen on maximizing its technological advancements in the field of bispecific and multispecific antibodies, methodically expanding its therapeutic matrix with the IO2.0 + ADC2.0 framework. Currently, there are two bispecific antibodies approved for cancer treatment within the company’s portfolio, showcasing Akeso’s commitment to cancer research.

The pipeline of innovative drug candidates continues to grow, with various clinical trials in progress that assess the combination of ivonescimab and cadonilimab with the next-generation ADCs, including AK138D1. Akeso’s determination to lead in the ADC space is evident through its diverse range of candidates, such as AK146D1, AK157D1, and more, with plans for clinical study initiation.

Conclusion

In summary, Akeso's commitment to advancing its innovative HER3 ADC technology holds promise for enhanced treatment protocols in lung cancer. The ongoing clinical studies aiming to redefine treatment paradigms in NSCLC may lead to improved patient outcomes and a significant shift in cancer care practices globally. As Akeso strives to build a formidable pipeline, its achievements could pave the way for novel therapies across various malignancies including lung cancer, breast cancer, and beyond. The future of cancer treatment underscores a progressive approach fueled by dedicated research, cutting-edge technology, and comprehensive patient care.